DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

NCT06176261 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

58

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Breast Cancer Female
Metastatic Triple-Negative Breast Carcinoma
ER Positive Breast Cancer
HER2-negative Breast Cancer
HER2 Negative Breast Carcinoma
ER-negative Breast Cancer

Interventions

DRUG: Datopotamab Deruxtecan

Sponsor

Sarah Sammons, MD

Collaborators

[object Object]